Ehab L. Atallah MD
Leadership Positions
Associate Director of the Cancer Service LinePublications (122)
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SdCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR) Blood Cancer Journal December 2024;14(1) SCOPUS ID: 2-s2.0-85185454442 12/01/2024 Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR) Blood Cancer J 2024 Feb 20;14(1):32 PMID: 38378617 PMCID: PMC10879201 SCOPUS ID: 2-s2.0-85185454442 02/21/2024 Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. (Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK) Am J Hematol 2024 Apr;99(4):606-614 PMID: 38342997 SCOPUS ID: 2-s2.0-85185125850 02/12/2024 Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. (Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE) JAMA Netw Open 2023 Dec 01;6(12):e2347950 PMID: 38109114 PMCID: PMC10728762 SCOPUS ID: 2-s2.0-85180310408 12/18/2023 Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review. (Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R) Ther Adv Hematol 2023;14:20406207221150305 PMID: 38105770 PMCID: PMC10725100 SCOPUS ID: 2-s2.0-85179719949 12/18/2023 Eligibility criteria: too big, too small or just right? (Atallah E) Haematologica 2023 Oct 12 PMID: 37822257 10/12/2023 Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia (Rezazadeh A, Deininger M, Atallah E) Current Treatment Options in Oncology August 2023;24(8):1036-1051 SCOPUS ID: 2-s2.0-85161400330 08/01/2023 Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy. (Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM) Leuk Res 2023 Sep;132:107348 PMID: 37423073 SCOPUS ID: 2-s2.0-85164434355 07/10/2023 Real-world Management of CML: Outcomes and Treatment Patterns. (Held N, Atallah EL) Curr Hematol Malig Rep 2023 Oct;18(5):167-175 PMID: 37395944 SCOPUS ID: 2-s2.0-85163857366 07/03/2023 Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. (Guru Murthy GS, Atallah E) Hematol Oncol Stem Cell Ther 2023 May 23;16(4):346-350 PMID: 37363977 SCOPUS ID: 2-s2.0-85163318224 06/26/2023 Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. (Rezazadeh A, Deininger M, Atallah E) Curr Treat Options Oncol 2023 Aug;24(8):1036-1051 PMID: 37300657 SCOPUS ID: 2-s2.0-85161400330 06/10/2023 Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. (Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K) Blood Adv 2023 Oct 10;7(19):5941-5953 PMID: 37267439 PMCID: PMC10562769 SCOPUS ID: 2-s2.0-85174324824 06/02/2023 3 CitationsSOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). (Mikhaeel S, Atallah E) Clin Lymphoma Myeloma Leuk 2023 May;23(5):333-339 PMID: 36934065 SCOPUS ID: 2-s2.0-85150380400 03/19/2023 Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). (Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR) Leukemia 2023 Apr;37(4):799-806 PMID: 36807649 SCOPUS ID: 2-s2.0-85148365155 02/23/2023 8 CitationsA Survey of Patient Experience in CML: American and Canadian Perspectives. (Hillis C, Flynn KE, Goldman EH, Moreira-Lucas TS, Visentini J, Dorman S, Ballinger R, Byrnes HF, De Palma A, Barbier V, Machado L, Atallah E) Patient Prefer Adherence 2023;17:331-347 PMID: 36760231 PMCID: PMC9904222 SCOPUS ID: 2-s2.0-85147714122 02/11/2023 Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. (Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D) J Cancer Res Clin Oncol 2023 Aug;149(9):6247-6262 PMID: 36707445 PMCID: PMC10356870 SCOPUS ID: 2-s2.0-85146935763 01/28/2023 3 CitationsTherapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review (Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R) Therapeutic Advances in Hematology January-December 2023;14 SCOPUS ID: 2-s2.0-85179719949 01/01/2023 Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. (Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E) Cancer 2023 Mar 15;129(6):934-945 PMID: 36545710 SCOPUS ID: 2-s2.0-85144909890 12/23/2022 2 CitationsOutcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. (Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ) Transplant Cell Ther 2023 Apr;29(4):265.e1-265.e10 PMID: 36526260 PMCID: PMC10189888 SCOPUS ID: 2-s2.0-85146459526 12/17/2022 7 CitationsHematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. (DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE) Transplant Cell Ther 2023 Feb;29(2):71-81 PMID: 36436780 SCOPUS ID: 2-s2.0-85145302399 11/28/2022 9 CitationsSafety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. (Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E) Leuk Res 2022 Dec;123:106984 PMID: 36401944 SCOPUS ID: 2-s2.0-85141943453 11/20/2022 1 CitationDasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. (Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M, Jeyakumar D, Yaghmour G, Atallah EL, Gerds AT, O'Brien SM, Liesveld JL, Othus M, Litzow M, Stone RM, Sharon E, Erba HP) Blood Adv 2023 Apr 11;7(7):1279-1285 PMID: 36322825 PMCID: PMC10090098 SCOPUS ID: 2-s2.0-85153621947 11/03/2022 8 CitationsCML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). (Sasaki K, Mauro MJ, Levy MY, Atallah EL, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE) Clin Lymphoma Myeloma Leuk 2022 Oct;22 Suppl 2:S299 PMID: 36163933 SCOPUS ID: 2-s2.0-85138139005 09/28/2022 Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A) J Health Econ Outcomes Res 2022;9(2):30-36 PMID: 35979529 PMCID: PMC9353133 08/19/2022 Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P) J Health Econ Outcomes Res 2022;9(2):19-29 PMID: 35979528 PMCID: PMC9352872 08/19/2022 A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. (Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, Atallah E) J Cancer Prev 2022 Jun 30;27(2):129-138 PMID: 35864858 PMCID: PMC9271408 07/23/2022 Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest? (Atallah E) Haematologica 2023 Apr 01;108(4):949-950 PMID: 35861019 PMCID: PMC10071108 SCOPUS ID: 2-s2.0-85151574213 07/22/2022 Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. (Pettit K, Rezazadeh A, Atallah EL, Radich J) Am Soc Clin Oncol Educ Book 2022 Apr;42:1-19 PMID: 35658498 06/07/2022 Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. (Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S) Leuk Res Rep 2022;17:100329 PMID: 35651540 PMCID: PMC9150024 SCOPUS ID: 2-s2.0-85131561638 06/03/2022 1 CitationRelapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. (Guru Murthy GS, Atallah E) JCO Oncol Pract 2022 Jul;18(7):489-490 PMID: 35588183 SCOPUS ID: 2-s2.0-85132353059 05/20/2022 1 CitationPatient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. (Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP) Haematologica 2022 Nov 01;107(11):2641-2649 PMID: 35511672 PMCID: PMC9614525 SCOPUS ID: 2-s2.0-85141308026 05/06/2022 4 CitationsOutcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. (Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM) Am J Hematol 2022 Jul;97(7):E232-E235 PMID: 35338673 SCOPUS ID: 2-s2.0-85127372897 03/27/2022 22 CitationsFollow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. (Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ) Blood 2022 Jun 09;139(23):3366-3375 PMID: 35081255 PMCID: PMC9197557 SCOPUS ID: 2-s2.0-85129375801 01/27/2022 50 CitationsChronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A) Journal of Health Economics and Outcomes Research 2022;9(2):30-36 SCOPUS ID: 2-s2.0-85136987579 01/01/2022 1 CitationChronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P) Journal of Health Economics and Outcomes Research 2022;9(2):19-29 SCOPUS ID: 2-s2.0-85136948288 01/01/2022 1 CitationTargeting TIM-3 as a new strategy in immunotherapy: focus on sabatolimab (Murthy GSG, Atallah E) Drugs of the Future November 2021;46(11):901-905 SCOPUS ID: 2-s2.0-85128303136 11/01/2021 1 CitationTreatment-Free Remission: the New Goal in CML Therapy. (Atallah E, Sweet K) Curr Hematol Malig Rep 2021 Oct;16(5):433-439 PMID: 34618317 PMCID: PMC8495665 SCOPUS ID: 2-s2.0-85116717959 10/08/2021 16 CitationsPatient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. (Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE) J Natl Cancer Inst 2022 Jan 11;114(1):160-164 PMID: 34491344 PMCID: PMC8755495 SCOPUS ID: 2-s2.0-85123645552 09/08/2021 10 CitationsMulti-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E) Bone Marrow Transplantation August 2021;56(8):1998-2004 SCOPUS ID: 2-s2.0-85103674051 08/01/2021 9 CitationsDo histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? (Badar T, Atallah E) Expert Opin Investig Drugs 2021 Jun;30(6):665-673 PMID: 33836635 SCOPUS ID: 2-s2.0-85104939879 04/11/2021 2 CitationsMulti-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E) Bone Marrow Transplant 2021 Aug;56(8):1998-2004 PMID: 33824440 SCOPUS ID: 2-s2.0-85103674051 04/08/2021 9 CitationsWhy isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making. (Atallah EL) Best Pract Res Clin Haematol 2021 Mar;34(1):101240 PMID: 33762095 SCOPUS ID: 2-s2.0-85100148584 03/26/2021 Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. (Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V) Leuk Lymphoma 2021 Jul;62(7):1730-1739 PMID: 33648418 SCOPUS ID: 2-s2.0-85110241807 03/03/2021 3 CitationsWhy isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making (Atallah EL) Best Practice and Research: Clinical Haematology March 2021;34(1) SCOPUS ID: 2-s2.0-85100148584 03/01/2021 Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. (Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E) Cancer 2021 Apr 01;127(7):1039-1048 PMID: 33259056 SCOPUS ID: 2-s2.0-85096971225 12/02/2020 16 CitationsAssessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. (Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE) JAMA Oncol 2021 Jan 01;7(1):42-50 PMID: 33180106 PMCID: PMC7662490 SCOPUS ID: 2-s2.0-85096163350 11/13/2020 45 CitationsDiscontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? (Atallah E, Schiffer CA) Haematologica 2020 Dec 01;105(12):2738-2745 PMID: 33054106 PMCID: PMC7716356 SCOPUS ID: 2-s2.0-85093538868 10/16/2020 Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS) Leuk Lymphoma 2021 Jan;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020 9 CitationsCamidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M) Leukemia Research August 2020;95 SCOPUS ID: 2-s2.0-85085967271 08/01/2020 24 CitationsReducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leukemia Research July 2020;94 SCOPUS ID: 2-s2.0-85084755644 07/01/2020 3 CitationsCamidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M) Leuk Res 2020 Aug;95:106385 PMID: 32521310 SCOPUS ID: 2-s2.0-85085967271 06/11/2020 24 CitationsReal-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. (Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E) Blood Adv 2020 May 26;4(10):2308-2316 PMID: 32453836 PMCID: PMC7252553 SCOPUS ID: 2-s2.0-85086878601 05/27/2020 26 CitationsReducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leuk Res 2020 Jul;94:106368 PMID: 32442786 SCOPUS ID: 2-s2.0-85084755644 05/23/2020 3 CitationsReal-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. (Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E) Clin Lymphoma Myeloma Leuk 2020 Aug;20(8):556-560.e2 PMID: 32291234 SCOPUS ID: 2-s2.0-85083004098 04/16/2020 13 CitationsImproving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E) J Natl Compr Canc Netw 2020 Feb;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.0-85079065513 02/06/2020 19 CitationsLoncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. (Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ) Blood Adv 2020 Feb 11;4(3):449-457 PMID: 32012214 PMCID: PMC7013258 SCOPUS ID: 2-s2.0-85082200332 02/06/2020 35 CitationsIn Reply. (Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2020 Apr;25(4):e744-e745 PMID: 31873972 PMCID: PMC7160403 SCOPUS ID: 2-s2.0-85076804489 12/25/2019 Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. (Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD) JAMA Oncol 2020 Apr 01;6(4):486-493 PMID: 31830234 PMCID: PMC6990739 SCOPUS ID: 2-s2.0-85076620276 12/13/2019 37 CitationsMusculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. (Kota V, Atallah E) Clin Lymphoma Myeloma Leuk 2019 Aug;19(8):480-487 PMID: 31171474 SCOPUS ID: 2-s2.0-85066428575 06/07/2019 11 CitationsPatients' perspectives on the definition of cure in chronic myeloid leukemia. (Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E) Leuk Res 2019 May;80:40-42 PMID: 30955853 SCOPUS ID: 2-s2.0-85063942202 04/09/2019 4 CitationsExploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. (Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2019 Sep;24(9):1253-1258 PMID: 30944185 PMCID: PMC6738285 SCOPUS ID: 2-s2.0-85063940883 04/05/2019 15 CitationsPracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. (Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E) Blood Adv 2019 Feb 26;3(4):508-518 PMID: 30760466 PMCID: PMC6391673 SCOPUS ID: 2-s2.0-85061620083 02/15/2019 59 CitationsTyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. (Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL) Leuk Lymphoma 2019 Jun;60(6):1476-1484 PMID: 30668234 SCOPUS ID: 2-s2.0-85060599029 01/23/2019 4 CitationsTreatment-Free Remission in CML: the US Perspective. (Guru Murthy GS, Atallah E) Curr Hematol Malig Rep 2019 Feb;14(1):56-61 PMID: 30645715 SCOPUS ID: 2-s2.0-85060169494 01/16/2019 11 CitationsIncidence and survival of T-cell acute lymphoblastic leukemia in the United States. (Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E) Leuk Lymphoma 2019 May;60(5):1171-1178 PMID: 30407885 SCOPUS ID: 2-s2.0-85057299329 11/09/2018 24 CitationsIncorporating newer agents in the treatment of acute myeloid leukemia. (Raj RV, Abedin SM, Atallah E) Leuk Res 2018 Nov;74:113-120 PMID: 30401522 SCOPUS ID: 2-s2.0-85055577100 11/08/2018 9 CitationsImplementation and evaluation of high-dose methotrexate administration guidelines. (Nowak TJ, Lorge AH, Rein LE, Canadeo AM, Frank JP, Samanas LC, Urmanski AM, Atallah EL) J Oncol Pharm Pract 2019 Oct;25(7):1675-1681 PMID: 30360674 SCOPUS ID: 2-s2.0-85059348123 10/27/2018 2 CitationsEpidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. (Guru Murthy GS, Pemmaraju N, Atallah E) Leuk Res 2018 Oct;73:21-23 PMID: 30189324 SCOPUS ID: 2-s2.0-85052637608 09/07/2018 67 CitationsAmebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. (Voshtina E, Huang H, Raj R, Atallah E) Case Rep Hematol 2018;2018:6514604 PMID: 30155323 PMCID: PMC6092972 08/30/2018 Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018 22 CitationsDesign and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. (Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE) BMC Cancer 2018 Apr 02;18(1):359 PMID: 29609532 PMCID: PMC5879565 SCOPUS ID: 2-s2.0-85044841612 04/04/2018 16 CitationsEarly Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018 Dasatinib dose management for the treatment of chronic myeloid leukemia. (Talpaz M, Saglio G, Atallah E, Rousselot P) Cancer 2018 Apr 15;124(8):1660-1672 PMID: 29370463 PMCID: PMC5901015 SCOPUS ID: 2-s2.0-85045130913 01/26/2018 18 CitationsWill tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? (Atallah E, Ritchie E) Expert Opin Pharmacother 2018 Feb;19(2):79-81 PMID: 29308683 SCOPUS ID: 2-s2.0-85041333482 01/09/2018 1 CitationChronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. (Narra RK, Flynn KE, Atallah E) Curr Hematol Malig Rep 2017 Oct;12(5):415-423 PMID: 28944397 PMCID: PMC6045428 SCOPUS ID: 2-s2.0-85029897925 09/26/2017 7 CitationsEarly mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017 4 CitationsChronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. (Khoury HJ, Williams LA, Atallah E, Hehlmann R) Am Soc Clin Oncol Educ Book 2017;37:468-479 PMID: 28561719 SCOPUS ID: 2-s2.0-85041303313 06/01/2017 12 CitationsRandomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP) J Clin Oncol 2017 Aug 20;35(24):2745-2753 PMID: 28486043 PMCID: PMC5562170 SCOPUS ID: 2-s2.0-85028505702 05/10/2017 187 CitationsRecipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017 8 CitationsRigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. (Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators) Lancet Oncol 2016 Apr;17(4):496-508 PMID: 26968357 SCOPUS ID: 2-s2.0-84959931622 03/13/2016 138 CitationsQuality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. (Flynn KE, Atallah E) Curr Hematol Malig Rep 2016 Apr;11(2):80-5 PMID: 26879546 PMCID: PMC4860261 SCOPUS ID: 2-s2.0-84958241812 02/18/2016 36 CitationsA Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. (Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H) Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):139-45 PMID: 26775883 PMCID: PMC5557033 SCOPUS ID: 2-s2.0-84958922276 01/19/2016 56 CitationsSafety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016 17 CitationsEfficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. (Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J) Leukemia 2016 Jun;30(6):1413-5 PMID: 26526986 PMCID: PMC4895165 SCOPUS ID: 2-s2.0-84948424356 11/04/2015 6 CitationsBortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 SCOPUS ID: 2-s2.0-84934862607 04/29/2015 25 CitationsEffects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):214-221.e1 PMID: 25682576 PMCID: PMC4418454 SCOPUS ID: 2-s2.0-84925412377 02/16/2015 61 CitationsLarge granular lymphocytic leukemia presenting late after solid organ transplantation: a case series of four patients and review of the literature. (Kataria A, Cohen E, Saad E, Atallah E, Bresnahan B) Transplant Proc 2014 Dec;46(10):3278-81 PMID: 25240311 SCOPUS ID: 2-s2.0-84926339267 09/23/2014 6 CitationsClinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. (Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V) Clin Lymphoma Myeloma Leuk 2015 Jan;15(1):e1-5 PMID: 25027569 PMCID: PMC4361182 SCOPUS ID: 2-s2.0-84934440451 07/17/2014 22 CitationsMyelodysplastic syndromes in the United States: an update for clinicians. (Troy JD, Atallah E, Geyer JT, Saber W) Ann Med 2014 Aug;46(5):283-9 PMID: 24716735 SCOPUS ID: 2-s2.0-84905448514 04/11/2014 18 CitationsTreatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643 SCOPUS ID: 2-s2.0-84896710555 01/09/2014 12 CitationsManagement of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA) Onco Targets Ther 2013;7:13-21 PMID: 24368888 PMCID: PMC3869911 SCOPUS ID: 2-s2.0-84890462687 12/26/2013 46 CitationsPhase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. (Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O) Clin Cancer Res 2014 Jan 15;20(2):490-8 PMID: 24178622 PMCID: PMC4310865 SCOPUS ID: 2-s2.0-84892716958 11/02/2013 95 CitationsClarifying the use of ruxolitinib in patients with myelofibrosis. (Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO) Oncology (Williston Park) 2013 Jul;27(7):706-14 PMID: 23977767 SCOPUS ID: 2-s2.0-84880293714 08/28/2013 9 CitationsImpact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). (Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM) Blood 2013 Sep 12;122(11):1974-82 PMID: 23847196 PMCID: PMC3772501 SCOPUS ID: 2-s2.0-84887389178 07/13/2013 83 CitationsEmerging drugs for myelofibrosis. (Atallah E, Verstovsek S) Expert Opin Emerg Drugs 2012 Dec;17(4):555-70 PMID: 23186315 PMCID: PMC5009610 SCOPUS ID: 2-s2.0-84870443079 11/29/2012 5 CitationsClinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. (Randhawa J, Wong S, Atallah E, Olasz E) Int J Dermatol 2014 Jan;53(1):e13-4 PMID: 22998756 SCOPUS ID: 2-s2.0-84890794842 09/25/2012 2 CitationsSplenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. (Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S) J Hematol Oncol 2012 Aug 01;5:43 PMID: 22852872 PMCID: PMC3464878 SCOPUS ID: 2-s2.0-84864416539 08/03/2012 28 CitationsMyeloproliferative neoplasms. (Kim J, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):177-94 PMID: 22449367 SCOPUS ID: 2-s2.0-84863382779 03/28/2012 9 CitationsChronic myelogenous leukemia for primary care physicians. (Torgerson SR, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):168-76 PMID: 22449366 SCOPUS ID: 2-s2.0-84858824580 03/28/2012 8 CitationsNilotinib cardiac toxicity: should we still be concerned? (Atallah E) Leuk Res 2011 May;35(5):577-8 PMID: 21333353 SCOPUS ID: 2-s2.0-79954594715 02/22/2011 9 CitationsLong term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. (Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J) Am J Hematol 2010 Aug;85(8):579-83 PMID: 20578198 PMCID: PMC3800118 SCOPUS ID: 2-s2.0-77955480515 06/26/2010 7 CitationsRecurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. (Angel JR, Parker S, Sells RE, Atallah E) Blood Coagul Fibrinolysis 2010 Jun;21(4):372-5 PMID: 20449891 SCOPUS ID: 2-s2.0-77951915862 05/08/2010 11 CitationsImatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8 PMID: 20332334 SCOPUS ID: 2-s2.0-77951554533 03/25/2010 95 CitationsExpression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. (Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH) Leuk Lymphoma 2010 Mar;51(3):481-7 PMID: 20141431 SCOPUS ID: 2-s2.0-79954619318 02/10/2010 5 CitationsResolution of rheumatoid arthritis symptoms with imatinib mesylate. (Vernon MR, Pearson L, Atallah E) J Clin Rheumatol 2009 Aug;15(5):267 PMID: 19654496 SCOPUS ID: 2-s2.0-69549097990 08/06/2009 10 CitationsPractical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21 PMID: 19621545 SCOPUS ID: 2-s2.0-63249106651 07/23/2009 12 CitationsProspect of JAK2 inhibitor therapy in myeloproliferative neoplasms. (Atallah E, Verstovsek S) Expert Rev Anticancer Ther 2009 May;9(5):663-70 PMID: 19445582 PMCID: PMC5176249 SCOPUS ID: 2-s2.0-68149160994 05/19/2009 27 CitationsMyeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. (Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E) Leuk Res 2009 Aug;33(8):1144-6 PMID: 19394693 SCOPUS ID: 2-s2.0-67349165083 04/28/2009 31 CitationsTreatment strategies in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Cancer Invest 2008 Mar;26(2):208-16 PMID: 18259954 SCOPUS ID: 2-s2.0-38949120072 02/09/2008 10 CitationsEpigenetic Drugs: DNA Demethylating Agents (Atallah E, Garcia-Manero G) Epigenetics in Biology and Medicine 1 January 2008:27-48 SCOPUS ID: 2-s2.0-85123129158 01/01/2008 Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. (Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S) Leukemia 2008 Jun;22(6):1295-8 PMID: 18059483 SCOPUS ID: 2-s2.0-45149121653 12/07/2007 26 CitationsUse of hypomethylating agents in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Clin Adv Hematol Oncol 2007 Jul;5(7):544-52 PMID: 17679928 SCOPUS ID: 2-s2.0-34848895438 08/08/2007 6 CitationsEstablishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H) Blood 2007 Nov 15;110(10):3547-51 PMID: 17673605 SCOPUS ID: 2-s2.0-36348930556 08/04/2007 69 CitationsCongestive heart failure is a rare event in patients receiving imatinib therapy. (Atallah E, Durand JB, Kantarjian H, Cortes J) Blood 2007 Aug 15;110(4):1233-7 PMID: 17449798 SCOPUS ID: 2-s2.0-34548030470 04/24/2007 214 CitationsEmerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. (Atallah E, Kantarjian H, Cortes J) Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S105-12 PMID: 17382019 SCOPUS ID: 2-s2.0-34249653546 03/27/2007 26 CitationsOptimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. (Atallah E, Cortes J) Curr Opin Hematol 2007 Mar;14(2):138-44 PMID: 17255791 SCOPUS ID: 2-s2.0-33846591021 01/27/2007 3 CitationsIn reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6 PMID: 17206119 SCOPUS ID: 2-s2.0-33846086176 01/09/2007 37 CitationsThe role of decitabine in the treatment of myelodysplastic syndromes. (Atallah E, Kantarjian H, Garcia-Manero G) Expert Opin Pharmacother 2007 Jan;8(1):65-73 PMID: 17163808 SCOPUS ID: 2-s2.0-33846078174 12/14/2006 27 CitationsAgent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? (Atallah E, Schiffer CA) Leuk Res 2007 May;31(5):720-1 PMID: 16956658 SCOPUS ID: 2-s2.0-34147180942 09/08/2006 2 CitationsGranulocyte transfusion. (Atallah E, Schiffer CA) Curr Opin Hematol 2006 Jan;13(1):45-9 PMID: 16319687 SCOPUS ID: 2-s2.0-33644848150 12/02/2005 37 CitationsTreatment of metastatic malignant melanoma. (Atallah E, Flaherty L) Curr Treat Options Oncol 2005 May;6(3):185-93 PMID: 15869730 SCOPUS ID: 2-s2.0-21744439869 05/05/2005 159 CitationsChronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9 PMID: 12115389 SCOPUS ID: 2-s2.0-0036604263 07/13/2002 18 Citations Last update: 03/28/2024